A collection of timely studies, news, treatment options and more is presented in this concise, invaluable resource.
Salary Survey reviews options and salary by state for making the transition to private practice…March 2019, AAOS Career Center Feature
Research Article. Journal of the American Academy of Orthopaedic Surgeons.
The Impact on early stage career growth and salary. July 2019, AAOS Career Center Feature.
The FDA approved a supplemental New Drug Application (sNDA) for enzalutamide, following FDA Priority Review designation, based on results from the phase III PROSPER trial. The FDA action broadens the indication for enzalutamide to men with castration-resistant prostate cancer (CRPC), now including men with non-metastatic CRPC.
The FDA approved a supplemental New Drug Application (sNDA) for enzalutamide, following FDA Priority Review designation, based on results from the phase III PROSPER trial. The FDA action broadens the indication for enzalutamide to men with castration-resistant prostate cancer (CRPC), now including men with non-metastatic CRPC.
More Surveys
Brought to you by Oncology Times
A collection of timely studies, news, treatment options and more is presented in this concise, invaluable resource.
Salary Survey reviews options and salary by state for making the transition to private practice…March 2019, AAOS Career Center Feature
Research Article. Journal of the American Academy of Orthopaedic Surgeons.
The Impact on early stage career growth and salary. July 2019, AAOS Career Center Feature.
The FDA approved a supplemental New Drug Application (sNDA) for enzalutamide, following FDA Priority Review designation, based on results from the phase III PROSPER trial. The FDA action broadens the indication for enzalutamide to men with castration-resistant prostate cancer (CRPC), now including men with non-metastatic CRPC.
The FDA approved a supplemental New Drug Application (sNDA) for enzalutamide, following FDA Priority Review designation, based on results from the phase III PROSPER trial. The FDA action broadens the indication for enzalutamide to men with castration-resistant prostate cancer (CRPC), now including men with non-metastatic CRPC.
More Surveys
Brought to you by Oncology Times